CSI Market
Sign In | Register

Trius Therapeutics Inc (TSRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TSRX Annual Cash Flow →
The table below presents a historical view of Trius Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2013)
6 Months 		(Mar 31 2013) (Sep 30 2012) (Jun 30 2012) (Mar 31 2012)
Operating Activities
Income-36.96
Depreciation & amortization0.36
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.46
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Gain Loss On Fair Value Adjustment Of Stock Warrant Liability-
Interest Accrual On Convertible Notes Payable-
Derivative Gain Loss On Derivative Net2.73
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable3.78
Increase (Decrease) in Accounts Payable-1.34
Increase (Decrease) in Accrued Liabilities-0.41
Recognition of Deferred Revenue-0.09
Increase (Decrease) in Prepaid Expense and Other Assets0.83
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.23
Discontinued operations0.00
Net Cash flow from Operating Activities-28.43
Investing Activities
Capital Expenditures-0.20
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities51.27
Payments to Acquire Available-for-sale Securities-56.10
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-5.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock32.40
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock Under Equity Line Of Credit Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities32.40
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.63
Total Cash Flow-1.05
4 historic quarters locked

Sign in to unlock the full Trius Therapeutics Inc cash flow history.

Sign In Create Free Account

About TSRX Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.